NASDAQ
Adaptimmune Therapeutics plc (ADAP) has a revenue compound annual growth rate of 175.49% over 5 years and 76.56% over 10 years. Revenue CAGR shows the compound annual growth rate of a company's total sales, indicating the pace of top-line expansion.
No price data available for this timeframe.